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Abstract
Acute renal failure (ARF) is seen mostly in Plasmodium falciparum infection, but P. vivax and P.
malariae can occasionally contribute for renal impairment.  Malarial ARF is commonly found in non-
immune adults and older children with falciparum malaria. Occurance of ARF in severe falciparum
malaria is quite common in southeast Asia and Indian subcontinent where intensity of malaria trans-
mission is usually low with occasional microfoci of intense transmission. Since precise mechanism
of malarial ARF is not known, several hypotheses including mechanical obstruction by infected eryth-
rocytes, immune mediated glomerular and tubular pathology, fluid loss due to multiple mechanisms
and alterations in the renal microcirculation, etc, have been proposed.  Increased fluid administration,
oxygen toxicity, and yet unidentified factors may contribute to pulmonary edema, acute respiratory
distress syndrome (ARDS), multiorgan failure and death. Mainstay of treatment consists of appropriate
antimalarial drug therapy, fluid replacement, and renal replacement therapy. Loop diuretics can con-
vert an oliguric renal failure to non-oliguric renal failure without affecting outcome of the disease
though the conversion reduces the risk of volume overload. There is little evidence on beneficial effect
of vasoactive drugs. Nephrotoxic drugs such as ACE inhibitors, NSAIDs, aminoglycosides, cepha-
losporins should be avoided. Currently, high quality intensive care, early institution of renal replace-
ment therapy, and avoidance of nephrotoxic drugs are standard practice of the prevention and man-
agement of ARF.
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Introduction
Malaria is caused by four species of the genus Plas-
modium namely, Plasmodium vivax, P. falciparum,
P. malariae and P. ovale. Common clinical presen-
tations of infection with all four Plasmodia species
are periodic paroxysm, chills, rigors, sweating, body
aches, headache, nausea, general weakness and pros-
tration. Severe life-threatening complications such as
cerebral malaria (CM), severe anemia, acidosis, res-
piratory distress, jaundice, acute renal failure (ARF),
acute respiratory distress syndrome (ARDS), etc
occur mostly with P. falciparum infection. A few
reports have appeared indicating association of
severe complications of malaria with P. vivax in-
fection1–3. Recently, life threatening complications
with P. knowlesi infection has been reported in
humans4. Renal involvement has been reported in
P. falciparum, P. malariae, and recently in P. vivax
infections. P. malariae associated nephropathy was
reported mainly from Africa, that too before 1980.
Publications on P. vivax renal failure are too few and
inconclusive to merit a detailed review. Therefore,
renal failure related to P. falciparum malaria will be
reviewed in detail while renal involvement in P.
malariae and P. vivax will be mentioned briefly.J  VECTOR  BORNE  DIS  45, JUNE 2008 84
Renal involvement in P. malariae infection: Inci-
dence of progressive glomerulonephritis was signifi-
cantly higher in malaria-endemic areas of Africa.
P. malariae was considered an important cause of
chronic malarial nephropathy (quartan malarial neph-
ropathy)5. The incidence of glomerulonephritis
gradually declined along with eradication of malaria
in many parts of Africa6,7. The disease affected
mostly children and presented as steroid-resistant
nephrotic syndrome. The pathogenesis of renal in-
volvement is possibly mediated through immune
complex deposition. Histopathologic observations
include features of mesangiocapillary glomerular,
and subendothelial immune complex deposits con-
taining IgG, C3, and malarial antigens. The disease
progresses to renal failure even after successful eradi-
cation of the infection. Quartan malarial nephropathy
was reported mainly from Africa6–12. However, most
evidences in favour of quartan malaria nephropathy
have been circumstantially linked with P. malariae
infection. A recent study in children from Ghana
could not notice any evidence for a dominant role of
steroid-resistant tropical glomerulopathies. Histo-
logical findings consisted of focal and segmental
glomerulosclerosis and minimal change disease.
Membrano-proliferative glomerulonephritis was
absent in almost all the cases. It was concluded that
a uniform pattern is not seen throughout Africa13. An-
other recent review on nephrotic syndrome in quar-
tan malaria inferred that the association between re-
nal involvement and P. malariae infection was only
coincidental and reported mostly before 1975. Cur-
rently, there is no evidence of chronic malarial
glomerulopathy in African children with nephrotic
syndrome14.
Renal involvement in P. vivax malaria: Renal in-
volvement in P. vivax malaria has been reported
mostly from Indian subcontinent. In one of the ear-
lier studies, Mehta et al15  observed that out of 24
patients of malarial ARF, 16 were infected with P.
falciparum, 3 with P. vivax, and 5 with mixed infec-
tion of P. falciparum and P. vivax. In a retrospective
analysis, 13 of the 93 patients of malarial ARF had P.
vivax infection, while another 6 had mixed infection
with P. falciparum and P. vivax.  Renal ischemia re-
sulting in acute tubular necrosis was considered re-
sponsible for the renal failure16. Evidence of renal in-
volvement was noticed in 2 cases of P. vivax malaria
from a total of 81 cases of malarial ARF in another
study17. In a study from Karachi, Pakistan, 3 out of
124 cases of malarial ARF had P. vivax infection
while the remaining 121 had P. falciparum infec-
tion18. Rare manifestations such as renal failure, ure-
mic encephalopathy, and thrombocytopenia were re-
ported in an 8-year-old boy with P. vivax malaria19.
Clinical pictures of toxic shock showing dissemi-
nated intravascular coagulation (DIC) with marked
thrombocytopenia, oliguric renal failure, and pulmo-
nary edema were found in patients with P. vivax ma-
laria from Republic of Korea20.
Epidemiology
Since malarial ARF is almost always caused by P.
falciparum infection, the discussions mentioned
below relates exclusively to ARF induced by P.
falciparum infection. ARF is a frequent and serious
complication of falciparum malaria in non-immune
adults and older children21–23. Proportion of ARF in
complicated falciparum malaria is several fold higher
in patients from non-malarious regions than those
from high malaria transmission areas. Malarial ARF
has been reported from several European countries,
where malaria transmission is virtually non-exis-
tent24,25. The incidence of ARF according to one re-
port is as high as that of CM26. In contrast, incidence
of ARF in falciparum malaria is absent or very low
in sub-Saharan Africa, particularly, from the areas of
intense malarial transmission, where younger chil-
dren are worst affected27,28. A large proportion of
malarial ARF patients admitted to a hospital in Ethio-
pia consisted of non-immune visitors29. However, in
recent years, malarial ARF with associated morbid-
ity and mortality is reported more frequently in semi-
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Occurrence of ARF in severe falciparum malaria is
quite common in southeast Asia and Indian subcon-
tinent where intensity of malaria transmission is usu-
ally low with occasional microfoci of intense trans-
mission. High incidence of malarial ARF has been
reported from Vietnam32. Subsequent studies have
proved the incidence to be even higher than that re-
ported earlier. Severe malaria in Vietnamese adults
is usually a multisystem disease where more than
40% of severe malaria patients had ARF, and more
than 55% of fatal cases had ARF on admission that
rose to 70% by the time they died33. Similarly, a sig-
nificant proportion of severe malaria patients in Thai-
land had ARF34. High incidence of ARF has also been
reported from other southeast Asian countries as well.
Hypercatabolic ARF associated with CM, heavy
parasitemia, and hyperbilirubinemia was noticed in
Malaysian patients35. ARF constituted 23.3% of se-
vere malaria patients in a hospitalized study from
Kampuchea. Coma stage III and multiorgan failure
were the most common causes of death36. Significant
proportion of severe malaria patients in Singapore
had ARF37.
In India, complications of P. falciparum malaria oc-
cur in all age groups but frequency of different com-
plications differs in children and adults. CM occurs
in equal frequency in children and adults and was the
common cause of mortality. Severe anemia and con-
vulsions were more common, jaundice less common,
ARF and ARDS rarely occurred in young children38.
There is a perceptible change in the clinical presen-
tation of severe malaria in India in last 10–15 years;
a gradual shift from single to multiple complications.
CM alone was the predominant complication in
adults earlier, where as currently, multiple complica-
tions are the usual presentation of severe malaria.
Mortality in CM patients with associated complica-
tions such as jaundice and ARF is twice as high as
that with CM alone. A significant increase in the in-
cidence of malarial ARF has been reported from sev-
eral centres across India. In 1982, a study from south-
ern part of Orissa state in eastern India indicated CM
as the predominant presentation of severe malaria.
Out of 173 cases of CM, renal involvement was ob-
served in 6% and hepatic involvement in 1%39.
Twenty years later a study from the same area and
same hospital showed 35% cases of severe P.
falciparum malaria having ARF. The study also in-
dicated an increase in incidence of malarial ARF,
from 95 cases in 1994 to 215 cases in 199840.  In
another large series published in 1989 Mehta et al41
did not find a single case of renal failure in 425 cases
of falciparum malaria. Malaria transmission in south
India is relatively less in comparison to eastern and
central India. Accordingly, malarial ARF was found
only occasionally in south India. However, in the
recent past, a significant change has been noticed in
the trend of ARF admissions. While ARF due to lep-
tospiral infection is on the decline, malaria has be-
come the emerging cause of ARF42. High incidence
of malarial ARF, both in children and adults has been
reported from several centres across the country15–17, 43–48.
A common inference from these studies is that the in-
cidence of ARF and jaundice is in the rise, and devel-
opment of multiple complications result in increased
mortality. A similar report from an intensive care unit
of a tertiary care university hospital also found ma-
laria as an important cause of multiorgan failure in
India and regardless of the organ system involved
mortality was significantly higher with multiple or-
gan failure than with one or no organ failure49. Stud-
ies from Pakistan also report malarial ARF contrib-
uting significantly to total ARF burden50.
Pathogenesis
Precise mechanism of renal failure in falciparum
malaria is not clearly known. Several hypotheses
including mechanical obstruction by infected eryth-
rocytes, immune mediated glomerular pathology,
fluid loss due to multiple mechanisms and alterations
in the renal microcirculation, etc have been pro-
posed21,22,51. Cytoadherence of P. falciparum infected
red blood cells (IRBCs) to the vascular endothelial
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mation is considered as a most important mechanism
of severe malaria. IRBCs preferentially sequester in
the deep vascular beds of vital organs, including the
brain, liver, lung, spleen, intestine, and kidney52–54.
Parasite proteins referred to as variant surface anti-
gens (VSA) expressed on the IRBC surface mediate
adhesion of infected erythrocytes to host vascular
endothelial receptors55,56. Significantly more IRBCs
were seen in renal vasculature of malaria patients
with ARF than those without ARF. However, the
extent of IRBC sequestration in glomerular and
tubulointerstitial capillaries was far less than the ce-
rebral vessels57. Thus, contribution of IRBC cyto-
adherence and clogging of the capillaries towards
pathogenesis of malarial ARF appears at best only
marginal.
Mononuclear cell infiltration in glomeruli and tub-
ulointerstitium has been reported in renal tissues
in severe falciparum malaria58-61. Other recent stud-
ies have also showed mononuclear cells in glomeru-
lar and peritubular capillaries though the number of
leukocytes was not significantly different between
the ARF group and the non-ARF group62,63. Margin-
ation of mononuclear cell to the brain capillary endo-
thelium has been demonstrated earlier in a significant
proportion of patients64. Activation of locally margin-
ated mononuclear cells within glomerular and
peritubular capillaries is likely to induce host immune
reactions by releasing cytokines, reactive oxygen
intermediates (ROI) and nitric oxide (NO) locally.
Further studies on the mechanism and effect of mono-
nuclear cell margination in the glomerular and
peritubular capillaries with special reference to local
release of soluble mediators will help in understand-
ing the pathogenesis of malarial ARF.
Exaggerated host immune response is considered an
important mechanism for several complications of
malaria. Host-parasite interaction may result in me-
chanical, immunologic and humoral responses,
which while eliminating parasite also injures host
tissues. Cytokines, ROI, and NO play an important
role in elimination of the parasite, though an unbal-
anced response may be responsible for pathogenesis
of severe malaria. Levels of inflammatory cytokines,
such as tumor necrosis factor alpha (TNF-α), inter-
feron gamma (IFN-γ), interleukins 1-alpha, 6, and 8
(IL-1α, IL-6, and IL-8) are elevated in malaria pa-
tients65. Higher concentrations of proinflammatory
cytokines are observed in severe complications of
malaria66–69. Anti-TNF-α and anti-IFN-γ antibodies
prevented occurrence of CM in experimental ma-
laria70. However, these effects could not be replicated
in human malaria except for amelioration of fever71.
Increased production of ROI and NO is commonly
found in malaria infection, but evidence on their role
in protection and pathogenesis of the disease has re-
mained inconclusive. ROI is considered to play a
significant role both in protection and pathogenesis
of malaria72,73. Higher blood concentrations of ROI
and depleted antioxidant defense system have been
observed in malaria patients74–76. The effect of NO
depends on its time of release and the type of isoform
released. While early increase of NO stimulates Th1
response to control parasitemia77, late increase of NO
production in the liver and spleen appear to have
pathological consequences78. Regulatory functions of
NO are dependent on the presence of various
isoforms of the enzyme nitric oxide synthase (NOS).
Constitutive NOS (cNOS) is responsible for continu-
ous synthesis of NO in low concentrations for impart-
ing its physiological functions. In contrast, inducible
NOS (iNOS) synthesize high levels of NO, which
plays a crucial role in pathological consequences.
Increased iNOS activity and production of NO was
observed in severe malaria79. During the blood stage
of malaria TNF-α upregulates NO synthesis either
alone or in combination with other cytokines80.
Restricted local blood flow in the kidneys is consid-
ered a major contributor for malarial ARF. Low in-
take of fluids, loss of fluids because of vomiting and
pyrexial sweating may be responsible for dehydration
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nal hypoperfusion, the spectrum of manifestations
varies from milder forms like pre-renal azotemia to
more severe forms of ischemic ARF. Pre-renal
azotemia is the most common form of renal impair-
ment resulting from mild to moderate renal hypo-
perfusion. It is rapidly reversible upon restoration of
renal blood flow. However, administration of
intravenous fluids often worsens the general condi-
tion of the patient by inducing pulmonary edema, a
situation similar to shock like syndrome. A general-
ized vasodilatation with an associated decrease in
systemic vascular resistance is considered an impor-
tant contributor for septic shock as well as malarial
ARF. Vasodilatation leads to activation of sympa-
thetic nervous system, rennin-angiotensin-aldoster-
one axis (RAAA), and release of vasopressin for
maintaining the falling blood pressure. Unfortu-
nately, these compensatory mechanisms may worsen
the renal pathology leading to overt ARF81,82 while
efficacy of these pressor hormones to raise blood
pressure through development of generalized vascu-
lar resistance is attenuated by higher hydrogen ion
and lactic acid concentrations. Hyperlactataemia is
considered a marker for poor prognosis in sepsis83 as
well as in malaria84,85.
Malarial ARF can occur as an isolated complication
or as a component of multiorgan involvement. Shock
and multiorgan failure is a common association in
malarial ARF as also in ARF of sepsis. In fact, exten-
sive similarities have been observed between the
sepsis and severe malaria in clinical presentation and
cytokine profile indicating that the two diseases op-
erate through very similar mechanisms86. Arterial
vasodilatation that accompanies sepsis is mediated,
at least in part by, cytokines that up-regulate the ex-
pression of iNOS in vasculature87,88. Plasma concen-
tration of several small and middle molecular weight
proteins is reduced in severe malaria because of
extravasations from vascular compartment to inter-
stitial space89,90. Even, the respiratory distress noticed
in severe malarial anemia may have been caused by
hypovolemia induced by vasodilatation rather than
volume overload biventricular failure91. In patients of
severe anemia administration of albumin for volume
expansion reduces mortality92. However, others did
not notice severe volume depletion or hypotension in
severe malaria93,94.
Low intake of fluids, loss of fluids because of vom-
iting and pyrexial sweating, cytokine and NO medi-
ated arterial vasodilatation specifically organ specific
release of NO, resistance to vasoactive hormones,
cytopathic hypoxia leading to decreased ATP synthe-
sis, cytoadherence of PRBCs, etc all may contribute
singly or in combination towards malarial ARF. In-
creased fluid administration, oxygen toxicity, and yet
unidentified factors may contribute to pulmonary
edema, acute respiratory distress syndrome (ARDS),
multiorgan failure and death (Fig. 1).
Histology
Various histologic pictures including glomerulone-
phritis, acute tubular necrosis (ATN), and interstitial
nephritis have been described in malarial ARF either
alone or in combination. Ultrastructural examination
of kidney of mice infected with P. berghei demon-
strated extensive cytoplasmic vacuolation in proxi-
mal tubular cells, thickened endothelial wall on
peritubular capillary, and swollen rough endoplasmic
reticulum and mitochondria. The lumen of vessels
contained parasitized erythrocytes and an inflamma-
tory infiltrate of macrophages95.
Contribution of glomerular pathology towards ma-
larial ARF is not clearly defined. Several studies have
reported histological evidence of glomerular lesions
in patients dying of falciparum malaria23,96,97. The
lesions were characterized by prominent mesangial
proliferation with modest matrix expansion, and oc-
casional basement membrane thickening. Deposition
of an eosinophilic granular material has been noticed
along the capillary walls, within the mesangium, and
in the Bowman’s capsule. The glomerular capillaries
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examination showed presence of IgM and C3 depos-
its in the capillary walls and in the mesangium. Elec-
tron microscopy showed subendothelial and mesangial
electron-dense deposits along with granular, fibrillar,
and amorphous material5,98. Presence of immune com-
plexes of P.  falciparum antigen in the glomerular
basement membrane and mesangium has also been
observed60. In P. falciparum infection high circulating
load of parasite antigens are observed because of cy-
clical rupture of IRBCs. An active host immune re-
sponse generating specific antiplasmodial antibodies
is likely to promote immune complex formation and
deposition in the capillary wall. However, clinical
presentation and urine examination findings do not
support presence of such deposits in malarial ARF. In
a recent study, deposition of immune complex was not
seen either in the basement membrane or mesangium
of glomeruli63. One important contributor for discrep-
ancy in the observations could be short duration of
disease process. Though enough plasmodial antigen
circulate in the blood during acute stage of the disease,
short duration of the disease process may not allow
enough time for the development of appropriate anti-
bodies for formation of circulating immune complexes
of the right structure to be deposited in the kidney.
ATN has been found as the most consistent histologi-
cal finding. Variable degrees of altered tubular cell
Fig. 1:  Mechanism of malarial acute renal failure (MNCs–Mononuclear cells; IRBCs–Infected red blood cells; RAAS– Renin-
angiotensin-aldosterone system; ROI–Reactive oxygen intermediates; NO– Nitric oxide; H+– Hydrogen ion)DAS: RENAL FAILURE IN MALARIA  89
morphology, beginning from cloudy swelling to cel-
lular necrosis are seen. Tubular changes include de-
posits of hemosiderin granular deposits, presence of
hemoglobin casts in the tubular lumen, and edema-
tous interstitium with mononuclear cellular infiltra-
tion. The venules may contain IRBCs and rosettes. A
recent study from Vietnam and Thailand found that
most patients showed mononuclear cells in glomeru-
lar and peritubular capillaries. Phagocytosed malarial
pigment was seen in the cytoplasm of mononuclear
cells in some patients63.
Acute interstitial inflammation is a well-recognized
pattern of malarial nephritis in experimental models
and after vaccination with P. falciparum antigens in
monkeys. It is considered a consequence of potent host
immune response. Though interstitial inflammation is
a common histopathologic association in malarial
ATN, isolated interstitial nephritis is uncommon.
Clinical presentation
Renal involvement in falciparum malaria can present
as electrolyte abnormality, abnormal urinary sediments
and increased urinary protein excretion, ARF, etc17.
ARF is usually associated with oliguria and in severe
cases even anuria. Occasionally ARF may be non-
oliguric, which makes the diagnosis difficult unless
serum creatinine is estimated. Pre-renal azotemia usu-
ally presents with clinical signs of severe dehydration.
However, prolonged anuria or oliguria may lead to in-
evitable expansion of extracellular fluid volume because
of diminished salt and water excretion. Oliguric phase
usually lasts about a week but may vary from few days
to few weeks. Malarial ARF is catabolic in type charac-
terized by rapid rise of plasma urea and creatinine due
to increased catabolism. Subclinical impairment of re-
nal function is also observed in a significant proportion
of malaria patients. Glomerular filtration rate (GFR)
assessed using cystatin C, was found elevated in 17%
children with falciparum malaria99.
The common predisposing factors for malarial ARF
are volume depletion, gastrointestinal bleed, sepsis,
nephrotoxic drugs (aminoglycosides and NSAID),
etc. Prognosis of malarial ARF depends on several
factors including other associated complications such
as CM, jaundice, shock, ARDS, severe anemia, high
plasma creatinine concentration, duration of ARF,
etc. Mortality is higher when plasma creatinine at
presentation is high, urine output is low, delayed re-
ferral to the hospital, and when associated with other
complications100.
Hyperbilirubinemia in falciparum malaria possibly
predisposes for ARF, which may remain unno-
ticed101. In an another study, nine patients of acute
falciparum malaria with severe hyperbilirubinemia
developed ARF, though interestingly, referral diag-
nosis did not include malaria as a cause of ARF in 8
out of 9 patients47. Simultaneously, malarial ARF was
significantly associated with liver dysfunction as
well32. The association between renal failure and
jaundice is a recurrent finding in studies on severe
malaria102–104. Other studies have also indicated that
almost all patients of ARF with jaundice had conju-
gated hyperbilirubinemia with cholestasis. This well
described association may contribute to the reduction
of GFR or development of ATN18,22. ARF associated
with jaundice had high mortality in comparison to
non-jaundiced ARF patients45,99.
Similarly, association of ARF with CM has been
reported from southeast Asia and Indian subcontinent
where malarial ARF is a common in P. falciparum
malaria. Out of 526 cases of CM reported from
Rourkela, in Sundargarh district of Orissa state, more
than 62% had associated severe complications in-
cluding 28.9% with ARF and 47.5% with jaundice.
Mortality in this series was particularly high (59%)
specifically in those with multiorgan failure105. The
effect of associated ARF on mortality in CM patients
indicated, mortality was as high as 39.5% when as-
sociated with ARF, while it was only 13.9% when
unassociated with ARF. For each one log unit in-
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creased by a factor of 10.8106. The association was
even higher in studies from Vietnam and Thailand.
About half of all adult patients with CM had bio-
chemical evidence of renal impairment (raised blood
urea and serum creatinine)32,107.
Management
Malarial ARF is suspected when urinary output falls
to less than 400 ml in 24 h or 20 ml/h, which fails to
improve after adequate rehydration. Occasionally
malarial ARF may be non-oliguric in which case
diagnosis can only be made from biochemical inves-
tigations. The diagnosis is confirmed when the serum
creatinine exceeds 3 mg/dL (260 μmol/L) in adults
and 1.5 mg/dL (130 μmol/L) in children. It is essen-
tial to distinguish between pre-renal azotemia and es-
tablished ARF for appropriate management. A
simple test to distinguish between the two is measure-
ment of urine specific gravity; while in pre-renal
azotemia it is more than 1.02, in established ARF it
is less than 1.01. The mainstay of treatment in ma-
larial ARF revolves around: (i) appropriate antima-
larial therapy; (ii) fluid replacement; (iii) renal re-
placement therapy; (iv) supportive therapy; and
(v) avoidance of nephrotoxic drugs.
Chloroquine is cheap, safe, and effective in chloro-
quine sensitive parasites, therefore, the preferred drug
of choice. However, chloroquine is no longer used for
treatment of severe falciparum malaria because of
widespread resistance of P. falciparum parasites to
the drug. The current practice is to treat all patients
of severe malaria including ARF with quinine or ap-
propriate artemisinin derivatives. The patients should
receive antimalarial drugs preferably through
parenteral route. Therapeutic window of quinine is
very small and higher blood concentration may lead
to severe cardiac toxicity108 and hypoglycemia by
inducing hyperinsulinimia109. Monitoring blood qui-
nine concentration and ECG changes can detect qui-
nine toxicity. Parenteral quinine dose should there-
fore, be reduced to half after 48 h if ARF is present.
Plasma concentration of 3-hydroxyquinine(3OHQn),
the main metabolite of quinine, may go up to 45% of
the plasma quinine level in malaria patients with
ARF. The metabolite possibly contributes to a signifi-
cant proportion of the antimalarial activity as well as
adverse effects of the parent compound, although this
metabolite is not quantitated routinely by current
high-performance liquid chromatography quinine
assays110. Quinine is not significantly removed by
continuous venovenous hemofiltration. The filter
clearance accounted for less than 1.5% of the total
body clearance111. Quinine was not detectable in
haemodialysate fluids and no significant change in
plasma quinine concentrations was noticed in ARF
patients during hemodialysis112. Malarial ARF sig-
nificantly modifies the pharmacokinetics of intra-
muscular artemether. The changes could be attributed
to improved absorption, bioavailability, a reduction of
systemic clearance, or a change in plasma protein bind-
ing of the drug. However, response of treatment in
relation to the parasite and fever clearance time, recru-
descence, and recovery of consciousness in comatose
patients were not different in patients with malarial
ARF than those without ARF113.
Preservation of renal blood flow and perfusion pres-
sure prevents deterioration of renal function. The first
step to achieve this is by infusion of fluids. The pa-
tient should be carefully examined for clinical fea-
tures of hypovolemia. Fluids should be administered
slowly and titrated against jugular venous pressure
and urine output, because of the vulnerability of ARF
patients for post-transfusional volume overload.
Composition of replacement fluids for treatment of
pre-renal azotemia due to hypovolemia must be tai-
lored according to the composition of the lost fluid.
Close monitoring for signs of volume overload dur-
ing transfusion of blood or fluids is essential.
Because of the hypercatabolic state of malarial ARF,
hemodialysis or peritoneal dialysis should be imme-
diately performed in conditions of rapid increase in
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fluid and waste products minimizes problem of fluid
overload and may prevent the progression of respira-
tory failure. More than half of malarial patients in
different series required dialysis. Early dialysis is
often indicated to take care of hypercatabolic state.
Although peritoneal dialysis is less effective because
of the complicating circulatory disturbances, it is
often the only available dialysis modality in areas
where malaria is endemic. Continuous arteriovenous
hemofiltration or continuous peritoneal dialysis is
considered superior. Beneficial effects of continuous
peritoneal dialysis have been observed in patients of
malarial ARF114. A comparative study to evaluate
efficacy of hemofiltration versus peritoneal dialysis
showed significant lower mortality with hemofiltra-
tion (15 vs 47%). The rates of resolution of acidosis
and decline in the serum creatinine concentration with
hemofiltration were more than twice than with peri-
toneal dialysis. Renal-replacement therapy was re-
quired for a significantly shorter period with
hemofiltration115. A systematic search of peer-re-
viewed publications studying dialysis support in
adults with ARF (of all causes) indicated intermittent
hemodialysis and continuous renal replacement
therapy appear to lead to similar clinical outcomes in
ARF patients. If continuous venovenous hemofiltra-
tion is used, a dose of 35 ml/kg per hour should be
provided116. Apheresis has been reported to success-
fully support anuric patients with cerebral and pulmo-
nary complications117.
Oliguria being a bad prognostic sign, diuretics are
often used to increase urine output in patients with or
at risk of ARF. Addition of vasoactive agents to boost
the efficacy of diuretics to restore renal blood flow
and perfusion pressure has yielded conflicting results.
Vasoactive drugs are often administered to improve
either cardiac output or mean arterial pressure in the
hope that renal blood flow will also be improved and,
thereby, renal protection achieved. While many of
these pharmacological approaches appear theoreti-
cally reasonable, their efficacy is uncertain. Furo-
semide in large doses along with dopamine at both
low and high doses has been tried with inconsistent
results. One study did not notice any beneficial effect
with intravenous furosemide at the dosage of 200 mg
6 hourly for a period of 4 days, but addition of
dopamine (1 μg/kg/min) increased creatinine clear-
ance and arrested the progress of renal failure when
the serum creatinine was less than 400 μmol/L, but
failed to alter the course of renal failure when the
serum creatinine exceeded 600 μmol/L118. Although
dopamine increased and epinephrine decreased frac-
tional renal blood flow, there was no evidence that
these drugs produced either a beneficial or a delete-
rious effect on renal oxygen metabolism or function
at any of the doses investigated119. Others have
opined that there is no evidence in favour of low-dose
dopamine preventing renal failure or improving re-
nal function. The addition of norepinephrine can be
of value if high doses of dopamine fail to restore
perfusion pressure120. A review of vasoactive drugs
and their effects on the kidney has inferred that none
have been demonstrated to achieve clinically impor-
tant benefits in terms of renal protection121. The re-
view concluded that there have been no randomized
controlled trials of sufficient statistical power to de-
tect differences in clinically meaningful outcomes
except for low-dose dopamine and there is a great
need for large randomized controlled trials to test the
clinical, instead of physiological, effects of vasoac-
tive drugs in critical illness.
Similarly, from a pathophysiological point of view
there are sound reasons to believe that loop diuretics
also could have a beneficial effect on renal function.
However, clinical trials on the prophylactic use of
loop diuretics rather point to a deleterious effect on
parameters of kidney function. In patients with estab-
lished ARF loop diuretics have been shown to in-
crease urine output, but a beneficial effect on renal
function has not been demonstrated122. Although
mannitol can flush out intratubular casts and in-
creases tubular flow, so far no well-designed clinical
studies have demonstrated its efficacy in ARF120.
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with control in the management of ARF did not no-
tice any association of diuretic use with reduction in
mortality or requirement for renal replacement
therapy. However, use of diuretics was associated
with shorter duration of renal replacement therapy
and increased urine output123.
In summary, appropriate antimalarial drug therapy,
fluid replacement, and renal replacement therapy
remains mainstay of treatment. Loop diuretics can
convert an oliguric renal failure to non-oliguric renal
failure. In spite of adequate urine volume, diuretics
do not usually affect outcome of the disease and se-
rum creatinine may continue to rise. However, con-
version of oliguric to non-oliguric renal failure re-
duces the risk of volume overload. There is little
evidence on beneficial effect of vasoactive drugs.
Nephrotoxic drugs such as ACE inhibitors, NSAIDs,
aminoglycosides, cephalosporins should be avoided.
Currently, high quality intensive care, early institu-
tion of renal replacement therapy, and avoidance of
nephrotoxic drugs are standard practices of the pre-
vention and management of ARF.
In spite of several research publications, mechanism
of malarial ARF and its effective management has
remained unclear. In addition, the literature is almost
silent on the mechanism of recent increase in inci-
dence of ARF and a shift towards multiple complica-
tions specifically in India. Though development of
chloroquine resistance has been suggested as possible
mechanism in a few publications, it has not been
substantiated by hard data. Other possible important
contributors could be rampant and indiscriminate use
of antibiotics and NSAID, indiscriminate use of
antimalarials for every fever, inadequate dosage of
antimalarials, use of spurious antimalarials, and other
parasite and host factors that have not been looked
into. While answer for these questions should be
looked into, of immediate concern is to understand
antimalarial drug metabolism and pharmacokinetics
in malaria patients with multiple complications, spe-
cifically those having both liver and kidney impair-
ment. Majority of antimalarial drugs are metabolized
in liver and excreted through kidneys. What happen
to their metabolism and excretion when both the or-
gans are involved needs to be clearly understood for
effective management and prevention of adverse
drug reactions.
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